Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

Mashup Score: 2

DAIC - November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial Fibrillation, show that rivaroxaban is comparable to warfarin, which is currently the standard of care anticoagulant prescribed for patients with bioprosthetic mitral valves, according to late-breaking research presented today at the 2020 American He

Read the full article here

Related Content